Frontiers in Pharmacology (Aug 2022)

Apatinib for recurrent/progressive glioblastoma multiforme: A salvage option

  • Hong-Hong Zhang,
  • Hong-Hong Zhang,
  • Xiao-Jing Du,
  • Mei-Ling Deng,
  • Lie Zheng,
  • Dun-Chen Yao,
  • Zhi-Qiang Wang,
  • Qun-Ying Yang,
  • Shao-Xiong Wu

DOI
https://doi.org/10.3389/fphar.2022.969565
Journal volume & issue
Vol. 13

Abstract

Read online

Purpose: The recurrent/progressive glioblastoma multiforme (GBM) carries a dismal prognosis and the definitive treatment strategy has not yet been established. This study aimed to assess the efficacy and safety of apatinib in recurrent/progressive GBM patients.Materials and methods: The clinical data of 19 recurrent/progressive GBM patients who received apatinib treatment from November 2015 to December 2019 at Sun Yat-sen University Cancer Center were collected retrospectively in this study. Objective response rate (ORR), disease control rate (DCR), progression-free survival (PFS), overall survival (OS), and treatment-related adverse events (AEs) were reviewed and assessed.Results: The overall ORR was 52.6%, and the DCR was 73.7%. Median PFS and OS were 5.1 and 10.4 months, respectively. The 6-month PFS and OS rates were 38.9% and 68.4%, respectively. The 12-month PFS and OS rates were 16.7% and 36.8%, respectively. The treatment-related toxicities were generally well-tolerated. The most common grade 3/4 AEs were hand-foot syndrome (36.8%) and hypertension (21.1%).Conclusion: Our study showed that apatinib therapy provided a better salvaging option for recurrent/progressive GBM patients and the toxicity was manageable.

Keywords